

Single-Base Editing of Cellular mRNA by CRISPR/Cas9

Genetic engineering is currently dominated by CRISPR/Cas9 technology, promising precise multipurpose genome editing. The 2016 WPI iGEM team investigated the potential of adapting this technology to direct single-base editing of mRNA by linking deactivated Cas9 to the C-to-U RNA editor enzyme APOBEC1. We pursued the re-cloning and characterization of the dCas9/APOBEC fusion to identify and eliminate problems related to expression and toxicity. Ultimately, this adapted CRISPR/Cas9 system could provide an advantageous method of editing, particularly for therapeutics.

Theory & Background

A Revolution in Synthetic **Biology: The "CRISPR" Way**

In CRISPR/Cas9 editing, Clustered **R**egularly-Interspaced Short Palindromic Repeats (CRISPRs) are recognized by the nuclease Cas9 and cleaved for the purpose of editing genomic DNA.

This system has been specially adapted for the use of targeting virtually any position in the genome by guiding the Cas9 to recognize specific sites of double-stranded DNA (dsDNA), usually via engineered single-guideRNAs (sgRNAs). The figure to the right shows a simplified diagram of how the CRISPR/Cas9 technology works.¹



Problems & Controversies with Current CRISPR/Cas9 Technology:

- Sequences similar to the target sequence are also cut, resulting in unpredictable and irreversible off-target effects
- Complex post-transcriptional modifications and splicing variation allow for a myriad of uncontrollable outcomes
- Accidental release of genetically modified organisms could lead to ecological disruptions or medical hazards
- Moral dilemma surrounds the idea of editing human genomes ²



Andrew Baker (Biochemistry & Biology/Biotechnology) and Kimberly Codding (Biochemistry & Professional Writing) Advisors: Professors Michael Buckholt and Natalie Farny (Biology/Biotechnology)

TransFectin. Allowed 4 hours before changing media.



Transfection Two



Continued Cloning of dCas9/APOBEC into pcDNA3.1+ Vector Suggestion \rightarrow future persistence in cloning in the dCas9 and APOBEC inserts with various size linkers into the pcDNA3.1+ and other standard vectors

Determining Alternate Transfection Protocols to Reduce Toxicity Suggestion \rightarrow find alternate methods of transfecting the DNA into the cells, in order to accurately determine the effect of the dCas9 construct(s)

References & Acknowledgements

• Professors Michael Buckholt and Natalie Farny, for their patient guidance, support, and enthusiasm with our project, especially during our stages of troubleshooting • The 2016 WPI iGEM team, for their previous work on the project

¹ Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013). Genome engineering using the CRISPR-Cas9 system. *Nature protocols, 8*(11), 2281-2308. ² Rodriguez, E. (2016). Ethical Issues in Genome Editing using Crispr/Cas9 System. *Journal of Clinical Research & Bioethics*, 2016.

³ WPI Worcester Team (2016). RICE CRISPRs: RNA Inosine/Uracil Conversion Editing Using CRISPR Technology. *iGem 2016*

⁴ Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A., & Liu, D. R. (2016). Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. *Nature*.

⁶ Gibson, D. G., Young, L., Chuang, R. Y., Venter, J. C., Hutchison, C. A., & Smith, H. O. (2009). Enzymatic assembly of DNA molecules up to several hundred kil ⁷ New England BioLabs, Inc. Instruction Manual: NEBuilder HiFi DNA Assembly Master Mix/NEBuilder HiFi DNA Assembly Cloning Kit. DNA Modifying Enzymes. (Accessed October 2016

Future Work



^b Registry of Standard Biological Parts. (n.d.) Help:Protocols. *iGem*. Accessed September 2016. http://parts.igem.org/wiki/index.php?title=Help:Contents&redirect=no